PLoS ONEplosplosonePLoS ONE1932-6203Public Library of ScienceSan Francisco, USAPONE-D-12-0273310.1371/journal.pone.0039891Research ArticleBiologyMicrobiologyBacteriologyBacterial physiologyHost-pathogen interactionMicrobial mutationChemistryPhysical chemistryChemical radicalsNitro radicalsMedicineClinical immunologyImmunityAdaptive immunityImmune defenseInnate immunityImmune cellsImmune responseInfectious diseasesBacterial diseasesTuberculosisViral diseasesHIVPulmonologyRespiratory infectionsChemistryImmunologyInfectious DiseasesMicrobiologyRespiratory MedicineResistance to First-Line Anti-TB Drugs Is Associated with Reduced Nitric Oxide Susceptibility in Mycobacterium tuberculosisNitric Oxide and Antibiotic Resistance in TBIdhJonna1*MekonnenMekidim23AbateEbba134WedajoWassihun3WerngrenJim5ÄngebyKristian6LermMaria1EliasDaniel7SundqvistTommy1AseffaAbraham3StendahlOlle1SchönThomas8Division of Microbiology and Molecular Medicine, Faculty of Health Sciences, Linköping University, Linköping, SwedenDepartment of Microbiology, Immunology and Parasitology, Addis Ababa University, Debre Zeit, EthiopiaArmauer Hansen Research Institute, Addis Ababa, EthiopiaDepartment of Microbiology and Parasitology, Gondar University Hospital, Gondar, EthiopiaUnit of Highly Pathogenic Microorganisms, Department of Preparedness, Swedish Institute for Communicable Disease Control, Solna, SwedenClinical Microbiology, MTC, Karolinska Institute, Karolinska University Hospital, Stockholm, SwedenDepartment of Cancer and Inflammation, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Infectious Diseases and Department of Clinical Microbiology, Kalmar County Hospital, Kalmar, SwedenDohertyT. MarkEditorStatens Serum Institute, Denmark* E-mail: jonna.idh@liu.se
Conceived and designed the experiments: JI MM JW KÃ, DE T. Sundqvist AA OS T. Schön. Performed the experiments: JI MM WW. Analyzed the data: JI MM ML T. Sundqvist OS T. Schön. Contributed reagents/materials/analysis tools: AA OS T. Schön. Wrote the paper: JI MM EA WW JW KÄ ML DE T. Sundqvist AA OS T. Schön.
The authors have declared that no competing interests exist.
2012296201276e39891261201228520122012Idh et alThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Background and Objective
The relative contribution of nitric oxide (NO) to the killing of Mycobacterium tuberculosis in human tuberculosis (TB) is controversial, although this has been firmly established in rodents. Studies have demonstrated that clinical strains of M. tuberculosis differ in susceptibility to NO, but how this correlates to drug susceptibility and clinical outcome is not known.
Methods
In this study, 50 sputum smear- and culture-positive patients with pulmonary TB in Gondar, Ethiopia were included. Clinical parameters were recorded and drug susceptibility profile and spoligotyping patterns were investigated. NO susceptibility was studied by exposing the strains to the NO donor DETA/NO.
Results
Clinical isolates of M. tuberculosis showed a dose- and time-dependent response when exposed to NO. The most frequent spoligotypes found were CAS1-Delhi and T3_ETH in a total of nine known spoligotypes and four orphan patterns. There was a significant association between reduced susceptibility to NO (>10% survival after exposure to 1 mM DETA/NO) and resistance against first-line anti-TB drugs, in particular isoniazid (INH). Patients infected with strains of M. tuberculosis with reduced susceptibility to NO showed no difference in cure rate or other clinical parameters but a tendency towards lower rate of weight gain after two months of treatment, independent of antibiotic resistance.
Conclusion:
There is a correlation between resistance to first-line anti-TB drugs and reduced NO susceptibility in clinical strains of M. tuberculosis. Further studies including the mechanisms of reduced NO susceptibility are warranted and could identify targets for new therapeutic interventions.
The study was supported by grants from the Swedish Research Council, Swedish International Development Agency (Sida) and the Swedish Heart-Lung Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Introduction
An important part of the host defence against Mycobacterium tuberculosis is nitric oxide (NO) produced by activated macrophages from L-arginine, molecular oxygen, and NADPH through the activity of inducible NO synthase (iNOS) [1]. Several animal and macrophage experiments have shown that NO and related reactive nitrogen species (RNS) constitute a major host defence mechanism against intracellular pathogens including, M. tuberculosis in both the acute and the latent phases of infection [2], [3]. It has also been shown that RNS are actively produced in human tuberculosis (TB), although their relative importance is controversial [4]–[9]. We have previously found that patients with TB have lower levels of NO in exhaled air and lower levels of NO metabolites in urine, compared to healthy controls [10], and that nutritional supplements of L-arginine can mediate clinical improvement in HIV-negative TB patients [11], [12].
Bicyclic nitroimidazoles are drug candidates currently in phase II trials for the treatment of tuberculosis [13], [14]. They are prodrugs, and one of the active metabolites generates RNS, which has been suggested to mediate the major anaerobic effect of the drug [15], [16]. It has also been shown that NO can contribute to the antimycobacterial action of the prodrug isoniazid (INH) [17]. The exact mechanisms of INH action are not fully understood, but during activation by mycobacterial catalase-peroxidase (encoded by the katG gen), several INH-derived intermediates and free radicals have been suggested to be of importance [17], [18].
Since previous studies have shown that susceptibility of mycobacteria to RNS can be strain-dependent [19]–[24], we here investigated the impact of relative NO susceptibility of M. tuberculosis on the clinical course of TB and in relation to drug resistance.
Materials and MethodsPatients
Patients presented here have previously been described in a clinical trial on arginine-rich food supplementation (ClinicalTrials.gov identifier: NCT00857402) were smear-positive patients with pulmonary TB, given Directly Observed Treatment Short course (DOTS) at Gondar University Hospital, Ethiopia, were consecutively asked to participate in the study. The inclusion criteria were age 15 to 60 years, willingness to take part in the study and no known chronic disease except TB and HIV. Baseline data for age, sex, HIV serostatus, presence of BCG scar, body mass index (BMI), body temperature, cough and haemoptysis was registered. Chest X-ray findings were graded as minimal, moderate or far advanced TB [25], and after two months of treatment as normal, marked regression, regression, stable disease or progression. Laboratory parameters, erythrocyte sedimentation rate (ESR), baseline acid-fast bacilli (AFB) smear grade, and NO metabolites in urine (as described by Verdon et al [26]) were measured. In the first eleven included subjects, exhaled NO was registered using an chemiluminescence NO analyser (NIOX, Aerocrine AB, Sweden) as previously described [27].
Identification and Spoligotyping of M. tuberculosis
One sputum specimen from each patient was kept at −20°C (as presented before) [28]. The sputum was decontaminated (modified Petroff’s method) and processed according to standard protocols [29] with subsequent inoculation on Lowenstein Jensen (LJ) slant media. M. tuberculosis was identified by a PCR-based approach built on genomic deletion analysis [30], and was carried out as described [31]. Spoligotyping was performed using a standard protocol [32] with the oligonucleotides DRa and DRb to amplify the direct repeat (DR) regions.
Drug Susceptibility Testing
Drug susceptibility testing for streptomycin (SM, 2 mg/L), isoniazid (INH, 1 mg/L), ethambutol (EMB, 5 mg/L) and rifampin (RIF, 1 mg/L) was performed using the indirect proportion method on LJ media, as recommended by WHO [33], [34]. When bacterial growth on the antibiotic-free media reached 50–100 colonies, a growth more than 1% on antibiotic-containing media was classified as resistant.
Susceptibility Testing for Nitric Oxide
M. tuberculosis from LJ medium was cultured in Middlebrook 7H9 broth supplemented with oleic acid-albumin-dextrose-catalase (OADC) until log phase (determined by bacterial growth as colony forming units (CFU) at different incubation periods, data not shown). Following washing in sterile PBS/0.05% Tween 80, a final concentration of 107 CFU/mL of bacteria were exposed in duplicates to 1 mM diethylenetriamine/nitric oxide adduct (DETA/NO, Sigma-Aldrich) and PBS (control) separately in Middlebrook 7H9 medium without OADC for 24 hours at 37°C. M. tuberculosis H37Rv (H37Rv) and M. bovis BCG (BCG) were used as reference strains in dose-response studies. The antimicrobial effect of DETA/NO was determined by viable count (CFUs) in tenfold dilutions on Middlebrook 7H10 plates supplemented with glycerol and 10% OADC.
Ethical Considerations
This study was conducted according to the principles expressed in the Declaration of Helsinki and the study was approved by the ethics committees at the Research and Publication Office at Gondar College of Medicine and Health Sciences, Ethiopian Science and Technology Commission, and Karolinska Hospital, Sweden. All study subjects were included only after obtaining written informed consent. For children below 18 years informed and written consent was obtained from parents or guardians.
Statistical Analyses
Data are presented as median and rang or first and third quartiles (Q1–Q3) if not stated otherwise. Numerical data were analysed with Mann-Whitney U-test, discrete data with Pearson’s Chi-square test and Fisher’s exact test, and p-values of less than 0.05 were considered as statistically significant. Multiple logistic regression analysis with a stepwise correction was applied on variables with a p-value less than 0.1 in the univariate analysis.
ResultsBaseline Characteristics
A total of 50 patients with confirmed culture- and smear-positive pulmonary TB were included in the study. The median age was 27 years (range 15–59), 50% (25/50) were female and 44% (22/50) were HIV-positive. Characteristics are presented in detail in table 1.
10.1371/journal.pone.0039891.t001
Characteristics for patients infected with strains of M. tuberculosis susceptible to NO or with reduced susceptibility to NO.
NO-susceptible
Reduced NO susceptibility
N
Median (Q1–Q3)
N
Median (Q1–Q3)
p
Characteristics
Age (years)
26
26.0 (20.8–37.0)
24
27.0 (23.2–37.0)
NS
BMI (kg/m2)
26
16.8 (15.6–18.0)
24
15.8 (14.7–17.4)
NS
Body temperature (°C)
25
37.6 (36.5–38.9)
24
37.8 (37.1–38.7)
NS
ESR week 0 (mm/h)
26
72.5 (50.0–85.5)
24
78.0 (67.5–88.5)
NS
ESR week 8 (mm/h)
25
44.0 (12.0–78.0)
24
41.0 (27.5–62.0)
NS
N
% (n)
N
% (n)
p
Females
26
46.2 (12)
24
54.2 (13)
NS
HIV
26
38.5 (10)
24
50.0 (12)
NS
BCG
26
11.5 (3)
24
12.5 (3)
NS
Cough week 0
26
100.0 (26)
24
100.0 (24)
NS
Cough week 8
25
64.0 (16)
24
29.2 (7)
<0.05
Haemoptysis week 0
26
23.1 (6)
24
20.8 (5)
NS
Haemoptysis week 8
25
8.0 (2)
24
4.2 (1)
NS
Weight gain from week 0 to 8
25
100.0 (25)
24
83.3 (20)
0.05
Sputum conversion week 8
26
84.6 (22)
24
83.3 (20)
NS
Chest X-ray week 0
Normal
19
0.0 (0)
16
0.0 (0)
NS
Minimal
19
26.3 (14)
16
25.0 (4)
NS
Moderately advanced
19
52.6 (10)
16
50.0 (8)
NS
Far advanced
19
21.1 (4)
16
25.0 (4)
NS
Chest X-ray week 8
Normal
16
0.0 (0)
15
6.7 (1)
NS
Marked regression
16
6.3 (1)
15
13.3 (2)
NS
Regression
16
62.5 (10)
15
66.7 (10)
NS
No change
16
25.0 (4)
15
13.3 (2)
NS
Progress
16
6.3 (1)
15
0.0 (0)
NS
Outcome
Cured
26
76.9 (20)
24
70.8 (17)
NS
Died
26
3.8 (1)
24
0.0 (0)
NS
Treatment failure
26
11.5 (3)
24
8.3 (2)
NS
Defaulter
26
3.8 (1)
24
12.5 (3)
NS
Transferred out
26
3.8 (1)
24
4.2 (1)
NS
Antibiotic resistance
Fully susceptible
26
96.2 (25)
22
66.7 (16)
<0.05
INH resistance
26
0.0 (0)
24
20.8 (5)
<0.05
SM resistance
26
3.8 (1)
24
8.3 (2)
NS
EMB resistance
26
0.0 (0)
24
0.0 (0)
NS
RIF resistance
26
0.0 (0)
24
4.2 (1)
NS
N
Median (Q1–Q3)
N
Median (Q1–Q3)
p
NO production
Urinary NO week 0 (mM)
26
1111 (792–1615)
24
1264 (931–1810)
NS
Urinary NO week 8 (mM)
25
1067 (961–1976)
24
1436 (881–2276)
NS
Exhaled NO week 0 (ppb)
11
15.8 (14.2–20.2)
8
12.4 (8.1–15.2)
NS
Exhaled NO week 8 (ppb)
11
15.7 (11.3–19.5)
8
15.0 (11.1–24.1)
NS
Q1–Q3 (quartile 1 to quartile 3); NO (nitric oxide); BMI (body mass index); ESR (sedimentation rate); INH (isoniazid); SM (streptomycin); EMB (ethambutol); RIF (rifampin). NO-susceptible and reduced NO-susceptible strains defined as ≤10% and >10% survival respectively after exposure to 1 mM DETA/NO. All patients were smear positive at week 0. Continuous data were tested with Mann-Whitney U-test and discrete data with Fisher’s exact test or Pearson’s Chi-square test.
Dose- and Time-dependent Response to NO
In order to determine doses and time points for the NO exposure, initial experiments with three randomly selected clinical isolates, one resistant to INH (coded RNI 027) and two fully susceptible to first-line anti-TB drugs (RNI 065 and RNI 066), were performed in duplicates. There was a dose- and time-dependent killing when exposed to DETA/NO (0.1–10 mM) (figure 1). After a 4-hour exposure to the selected dose of 1 mM DETA/NO, the mean survival rate of the strains for the clinical isolates was 68% (RNI 027), 62% (RNI 065), and 71% (RNI 066). In H37Rv and BCG, the survival rate was 45% and 57% respectively. The response was time-dependent and 24 hours post-exposure, the survival decreased to 23% (RNI 027), 13% (RNI 065) and 12% (RNI 066) for the clinical isolates and to 9% and 17% for H37Rv and BCG, respectively (figure 1b).
10.1371/journal.pone.0039891.g001
Dose- and time-dependent killing of M. tuberculosis exposed to NO.
Survival of three clinical strains, H37Rv and BCG after exposure to 1 mM of the NO donor DETA/NO for 4 and 24 hours (A). Survival of the three clinical strains exposed to different doses of DETA/NO for 24 hours (B). Survival was determined through viable count (colony forming units, CFU) and each point represents a mean value of duplicates.
Association between Reduced Susceptibility to NO and Resistance to First-line anti-TB Drugs
Drug susceptibility testing showed an overall resistance rate to first-line anti-TB drugs of 18% (9/50). The most frequent resistance was found against INH (10%, 5/50) followed by SM (6%, 3/50) and RIF (2%, 1/50). No strains resistant to EMB and no multidrug-resistant (MDR) TB strains were isolated in this study. The ratio of resistant strains did not differ between HIV-positive and HIV-negative individuals (14% (3/22) vs. 21% (6/28), p = 0.713).
The median survival in the 50 clinical isolates, 24 hours post exposure to 1 mM DETA/NO, was 10% and showed a variation between 0 to 60% when compared to a control exposed to PBS (p<0.001, figure 2). For further comparison of susceptibility to NO with drug resistance and clinical outcome, reduced susceptibility to DETA/NO was defined as >10% survival (1 log10) after exposure to 1 mM DETA/NO for 24 hours compared to the control exposed to PBS.
10.1371/journal.pone.0039891.g002
Reduced NO susceptibility in spoligotype-based clusters of M. tuberculosis.
Survival of clinical isolates 24 hours after exposure to the NO donor DETA/NO. Presence of resistance to first-line anti-TB drugs is indicated with circles; isoniazid (INH), streptomycin (SM) and rifampin (RIF). Each point represents a mean value of duplicates and the dashed line is the median survival of all 50 isolates.
Strikingly, no INH resistance was detected among NO-susceptible strains and the median survival of INH-resistant isolates exposed to DETA/NO was 53% (Q1–Q3, 32–57%, n = 5) compared to 10% (Q1–Q3, 0–25%, n = 45, p = 0.006) in INH-susceptible isolates.
Clinical Response in Relation to NO Susceptibility of M. tuberculosis
Infection with strains of M. tuberculosis with reduced susceptibility to NO did not correlate to the final clinical outcome according to WHO (cured, died, treatment failure, defaulter or transferred out; table 1), but there was a tendency to a lower rate of weight gain after 8 weeks of treatment (83% (20/24) vs. 100% (25/25), p = 0.05). Three out of the four study subjects who did not increase in weight during the 8 first weeks of treatment were HIV-positive, but there was no statistical difference in weight gain overall between HIV-positive and HIV-negative TB patients (86% (18/21) vs. 96% (27/28), p = 0.301). Nor did patients infected with drug-resistant strains differ in their rate of weight gain compared to patients with drug-susceptible strains (8/9, 89% vs. 37/40, 93%, p = 0.569).
Multiple Logistic Regression Analysis
The multiple logistic regression analysis showed that reduced NO susceptibility was associated to drug resistance also when age, sex, HIV status and supplementation of arginine-rich food were included in in the analysis (OR 19.00; 95% CI (1.67–215.52), p = 0.019, n = 50, table 2).
10.1371/journal.pone.0039891.t002
Multiple logistic regression analysis comparing strains of M. tuberculosis susceptible to NO with strains of reduced susceptibility to NO.
Reduced NO susceptibility
Univariate
Multivariate
Parameter
N
n
%
OR (95% conf. int.)
p
OR (95% conf. int.)
p
Age
≤28
30
13
43.4
1.00
1.00
>28
20
11
55.0
1.60 (0.50–5.15)
0.424
2.34 (0.50–10.96)
0.275
Gender
M
25
11
44.0
1.00
1.00
F
25
13
52.0
1.38 (0.44–4.32)
0.574
2.55 (0.63–10.25)
0.182
HIV
No
28
12
42.9
1.00
1.00
Yes
22
12
54.5
1.60 (0.50–5.07)
0.417
1.72 (0.41–7.27)
0.454
Arginine supplementation
No
24
14
58.3
1.00
1.00
Yes
26
10
38.5
0.45 (0.14–1.43)
0.169
0.38 (0.09–1.53)
0.168
Resistance to first- lineanti-TB drugs
No
41
16
39.0
1.00
1.00
Yes
9
8
88.9
12.50 (1.34–116.53)
0.027
19.00 (1.67–215.52)
0.019
Spoligotype Patterns
Of the 50 clinical strains 47 (94%) were successfully typed by conventional spoligotyping technique [32]. The isolates were identified as five orphan spoligotypes and nine spoligotypes present in the M. tuberculosis molecular markers database (SITVIT) and compared to the fourth international spoligotyping database (SpolDB4) for classification [35]–[37]. The most common spoligotypes were CAS1-Delhi (28%, 13/47) and T3_ETH (23%, 11/47). Although the spoligotype-based clusters differed in susceptibility to NO, our sample size was not sufficient to investigate any significant differences between the clusters (figure 2).
Discussion
The main finding of this study is that reduced susceptibility to NO in clinical strains of M. tuberculosis was associated with resistance to first-line drugs against TB. As previously reported, certain strains of M. tuberculosis can to some extent resist RNS generated in vitro as acidified nitrite (M. intracellulare 31F093T, KUMS 9007 [19], M. tuberculosis CDC1551, CB3.3 [23], M. bovis, M. tuberculosis 79499 [21], a C strain cluster defined by IS6110-based strain-typing [20], and the genotypes G1, G2, S2, U [24]). Since the acid has a bactericidal effect in itself and actually potentiates the effect of NO [38], it has been acknowledged that the new generation NO donors (DETA/NO) can better mimic a prolonged release with low levels of NO similar to the production in vivo[39]. In dose-response experiments for three clinical strains, we found that there was a dose-dependent killing by one log10 at 1 mM DETA/NO and by 2 log10 for 10 mM DETA/NO. The level of inhibition by NO at 24 hours was between 0.5 to 2 log10 for 1 mM DETA/NO, which could be compared to the early effect of bactericidal drugs such as INH [40]. To discriminate difference in susceptibility to NO between clinical strains, we used a cut-off for reduced NO susceptibility at 10% survival after 24 hours compared to control, which is similar to the wild type distribution used for defining critical concentrations for M. tuberculosis[33]. Lower doses of DETA/NO have been used to induce expression of latency-associated genes such as dosR[41], [42]. The effect of NO is likely to be increased if investigated at later time points as for anti-TB drugs, since killing of M. tuberculosis takes more time relative to other bacteria with higher replication rates such as E. coli. The analysis was blinded to antibiotic resistance data, and a high level of antibiotic resistance was observed in the isolates with reduced NO susceptibility. Strikingly, no INH resistance was detected among NO-susceptible strains but on the other hand reduced NO susceptibility was not exclusively found among INH-resistant strains. INH is a prodrug that needs activation by the katG-encoded mycobacterial catalase-peroxidase, where several INH-derived intermediates including free radicals have been suggested to contribute to the overall antimycobacterial action of INH [17], [18]. We did not verify the genetic location of the INH resistance, although the katG-mutation is the predominant cause of INH resistance in strains of M. tuberculosis from Ethiopia [43]. It has previously been shown that the loss of katG could render the bacteria susceptible to reactive oxygen species (ROS) and RNS, and a compensatory up-regulation of the alkyl hydroperoxidase (ahpC) gene could be the explanation for the increased resistance to NO as a compensatory survival strategy of INH-resistant bacteria [44]–[46]. Other candidates for antioxidant systems up-regulated by M. tuberculosis during oxidative stress are thioredoxin-dependent peroxidases (TPx), resulting in tolerance to peroxides produced by the immune system [42]. Most likely, it is a combination of the expression of genes upon exposure to reactive species, the resistance of the M. tuberculosis cell wall itself, and up-regulation of genes to repair damaged proteins and DNA, that result in reduced susceptibility against ROS and RNS in M. tuberculosis[42]. The most frequent spoligotypes were CAS1Delhi and T3_ETH and a more accurate identification of genetic relationship among the isolates is likely to better have identified differences among the strains in respect to susceptibility to NO.
Although the small sample size is a limitation, no correlation was found between susceptibility of M. tuberculosis to NO and treatment outcome, but there was a tendency towards lower rate of weight gain after 8 weeks of treatment, in subjects infected with M. tuberculosis with reduced susceptibility to NO. To draw a more definitive conclusion on whether this result was confounded by the presence of antimycobacterial drug resistance, a larger sample size is needed.
In a situation of increasing MDR and extensively drug-resistant (XDR) TB, new drug targets are needed [47]. NO is produced in activated macrophages during TB [1], [8], [9] and based on the correlation between reduced susceptibility to NO and resistance to first-line anti-TB drugs, the relative importance of oxidative defence mechanisms in M. tuberculosis needs to be further investigated.
The authors wish to thank Nurse Meseret Senbeto, Mr Tezera Jemere, Ms Saba Ekubay, and Mr Belay Anagaw for invaluable support in monitoring patients and handling patient samples. We also wish to thank the study participants without whom the study would not have been possible.
ReferencesNathanCShilohMU2000Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens.9788418848ChanEDChanJSchlugerNW2001What is the role of nitric oxide in murine and human host defense against tuberculosis?Current knowledge.25606612ScangaCAMohanVPTanakaKAllandDFlynnJL2001The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice.6977117717LiuPTModlinRL2008Human macrophage host defense against Mycobacterium tuberculosis.20371376NicholsonSBonecini-Almeida MdaGLapa eSilvaJRNathanCXieQW1996Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis.18322932302RichEATorresMSadaEFineganCKHamiltonBD1997Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB.78247255RockettKABrookesRUdalovaIVidalVHillAV19981,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line.6653145321SchonTElmbergerGNegesseYPandoRHSundqvistT2004Local production of nitric oxide in patients with tuberculosis.811341137ChoiHSRaiPRChuHWCoolCChanED2002Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis.166178186IdhJWestmanAEliasDMogesFGetachewA2008Nitric oxide production in the exhaled air of patients with pulmonary tuberculosis in relation to HIV co-infection.8146MacallanDC1999Malnutrition in tuberculosis.34153157SchonTEliasDMogesFMeleseETessemaT2003Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis.21483488NathanC2008Microbiology. An antibiotic mimics immunity.32213371338GurumurthyMMukherjeeTDowdCSSinghRNiyomrattanakitP2012Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.279113125SinghRManjunathaUBoshoffHIHaYHNiyomrattanakitP2008PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.32213921395ManjunathaUBoshoffHIBarryCE2009The mechanism of action of PA-824: Novel insights from transcriptional profiling.2215218TimminsGSMasterSRusnakFDereticV2004Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis.4830063009TimminsGSDereticV2006Mechanisms of action of isoniazid.6212201227DoiTAndoMAkaikeTSugaMSatoK1993Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis.6119801989FriedmanCRQuinnGCKreiswirthBNPerlmanDCSalomonN1997Widespread dissemination of a drug-susceptible strain of Mycobacterium tuberculosis.176478484O’BrienLCarmichaelJLowrieDBAndrewPW1994Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro.6251875190RhoadesEROrmeIM1997Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates.6511891195FirmaniMARileyLW2002Mycobacterium tuberculosis CDC1551 is resistant to reactive nitrogen and oxygen intermediates in vitro.7039653968InumaruVTNogueiraPAButuemIVRileyLWFerrazoliL2009Reactive nitrogen intermediate susceptibility of Mycobacterium tuberculosis genotypes in an urban setting.13665668AmericanST1961National tuberculosis association of the USA diagnostic standards and classification of tuberculosis.VerdonCPBurtonBAPriorRL1995Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite.224502508SchonTIdhJWestmanAEliasDAbateE2011Effects of a food supplement rich in arginine in patients with smear positive pulmonary tuberculosis - A randomised trial.91370377MekonenMAbateEAseffaAAnagawBEliasD2010Identification of drug susceptibility pattern and mycobacterial species in sputum smear positive pulmonary tuberculosis patients with and without HIV co-infection in north west Ethiopia.48203210(HPA). HPA2003Standard Operating Procedure: investigation of specimens for mycobacterium species.BroschRGordonSVMarmiesseMBrodinPBuchrieserC2002A new evolutionary scenario for the Mycobacterium tuberculosis complex.9936843689ParsonsLMBroschRColeSTSomoskoviALoderA2002Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis.4023392345KamerbeekJSchoulsLKolkAvan AgterveldMvan SoolingenD1997Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology.35907914CanettiGFoxWKhomenkoAMahlerHTMenonNK1969Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.412143NCCLSNCfCLS2000Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actinomycetes;tentative standard – second edition.BrudeyKDriscollJRRigoutsLProdingerWMGoriA2006Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology.623Institut GldP2011SITVITWEB.Available: http://www.pasteur-guadeloupe.fr:8081/SITVITDemo/.Accessed 2011 Oct.DemayCLiensBBurguiereTHillVCouvinD2012SITVITWEB - A publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology.12755766JackettPSAberVRLowrieDB1978Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis.1043745KeeferLKNimsRWDaviesKMWinkDA1996“NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms.268281293GumboTLouieALiuWBrownDAmbrosePG2007Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.5123292336VoskuilMISchnappingerDViscontiKCHarrellMIDolganovGM2003Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program.198705713VoskuilMIBartekILViscontiKSchoolnik GK2011The response of mycobacterium tuberculosis to reactive oxygen and nitrogen species.2105AbateGHoffnerSEThomsenVOMiornerH2001Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG.20329333ShermanDRMdluliKHickeyMJArainTMMorrisSL1996Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis.27216411643ChenLXieQWNathanC1998Alkyl hydroperoxide reductase subunit C (AhpC) protects bacterial and human cells against reactive nitrogen intermediates.1795805Sherman DR, Mdluli K, Hickey MJ, Barry CE 3rd, Stover CK1999AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis.10211217GandhiNRNunnPDhedaKSchaafHSZignolM2010Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.37518301843